Abstract:
Provided herein are glycovariant Fc fusion proteins having increased serum half lives. Also provided are methods for increasing the serum half life of an Fc fusion protein by introducing one or more non-endogenous glycosylation sites.
Abstract:
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. In certain aspects, the disclosure demonstrates that antagonists of BMP9 and/or BMP10, ligands for ALK1, may also be used to inhibit angiogenesis in vivo.
Abstract:
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Abstract:
Method and system for managing a storage environment having a cluster based storage system and a non-cluster based storage system is provided. A management application collects information regarding components of both the cluster based storage system and the non-cluster based storage system. A layout having a plurality of data structures is generated and maintained by the management application. The data structures include information regarding the components and their relationships with each other, if any. The layout is used for responding to user requests and presenting an integrated view of the storage environment on a display device with selectable options for selecting the cluster based storage system components and the non-cluster based storage system components.
Abstract:
A novel P-selectin ligand glycoprotein is disclosed, comprising the amino acid sequence set forth in SEQ ID NO:2 or by the amino acid sequence set forth in SEQ ID NO:4. DNA sequences encoding the P-selectin ligand protein are also disclosed, along with vectors, host cells, and methods of making the P-selectin ligand protein. Pharmaceutical compositions containing the P-selectin ligand protein and methods of treating inflammatory disease states characterized by P-selectin- and E-selectin-mediated intercellular adhesion are also disclosed.
Abstract translation:公开了一种新型P-选择素配体糖蛋白,其包含SEQ ID NO:2所示的氨基酸序列或SEQ ID NO:4所示的氨基酸序列。 还公开了编码P-选择素配体蛋白的DNA序列,以及载体,宿主细胞和制备P-选择蛋白配体蛋白的方法。 还公开了含有P-选择素配体蛋白质的药物组合物和治疗由P-选择蛋白和E-选择素介导的细胞间粘附特征的炎性疾病状态的方法。
Abstract:
A system and method for determining differences between configurations of a software program. A configuration differencing command generates a hash table of configuration keys and values for each of the configurations being compared. A key is selected from a first hash table and the command determines if an identical key exists in the second hash table. If the key exists in the second hash table, a comparison is made of the values associated with the keys and, if the values are not identical, the configuration differencing command displays the differences to an administrator.
Abstract:
The disclosure relates to Cerberus/Coco polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11.
Abstract:
In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.
Abstract:
In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.